Cryptic Parasite Revealed. Improved Prospects for Treatment and Control of Human Cryptosporidiosis Through Advanced Technologies {star operator}

Advances in Parasitology

Volumn 77, Issue , 2011, Pages 141-173

  Jex, Aaron R ^a   Smith, Huw V ^b   Nolan, Matthew J ^a   Campbell, Bronwyn E ^a   Young, Neil D ^a   Cantacessi, Cinzia ^a   Gasser, Robin B ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b STOBHILL HOSPITAL   (United Kingdom)

Author keywords

Cryptosporidium; Drug targets; Essentiality; Genomics; Transcriptomics

Indexed keywords

ADENOSINE PHOSPHATE; ANTIPROTOZOAL AGENT; CHLORAMPHENICOL; CHLORIDE ION; CLARITHROMYCIN; CYSTEINE PROTEINASE; DIHYDROFOLATE REDUCTASE; DIHYDROSTREPTOMYCIN; ENZYME INHIBITOR; FUSIDIC ACID; GUANOSINE PHOSPHATE; GUANOSINE TRIPHOSPHATASE INHIBITOR; HYGROMYCIN; INOSINATE DEHYDROGENASE; NEOMYCIN; PROTEIN ZO1; PROTOZOAL PROTEIN; PURINE DERIVATIVE; PYRIMETHAMINE; PYRIMIDINE DERIVATIVE; RIBOSTAMYCIN; SALINOMYCIN; SPARSOMYCIN; SPIRAMYCIN; STREPTOGRAMIN; SUBSTANCE P; TETRACYCLINE; THOMBROSPONDIN RELATED ATTACHMENT PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; ASEXUAL REPRODUCTION; CD4+ T LYMPHOCYTE; CELL CULTURE; CELL FREE SYSTEM; CHLORIDE TRANSPORT; CHOLECYSTITIS; CHOLESTATIC HEPATITIS; CHRONIC DISEASE; COMPUTER MODEL; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM HOMINIS; CRYPTOSPORIDIUM MELEAGRIDIS; CRYPTOSPORIDIUM PARVUM; CYTOSKELETON; DEHYDRATION; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; ENERGY YIELD; FECES; GENE SEQUENCE; GENETIC TRANSCRIPTION; HOST PARASITE INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; INFLAMMATION; INTESTINE CELL; INTESTINE MUCOSA PERMEABILITY; MALABSORPTION; MALARIA; MEROZOITE; MOLECULAR DIAGNOSIS; MOLECULAR DOCKING; NATURAL KILLER CELL; NONHUMAN; OOCYST; PANCREATITIS; PARASITE DEVELOPMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEOMICS; PURINE SYNTHESIS; SCHIZONT; SPOROZOITE; STOMACH DISEASE; TOXOPLASMOSIS; TRANSCRIPTOMICS; TRANSGENICS; TROPHOZOITE; TRYPANOSOMIASIS;

EID: 82555165205     PISSN: 0065308X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-391429-3.00007-1     Document Type: Chapter

References (222)

1. Abrahamsen M.S., Templeton T.J., Enomoto S., Abrahante J.E., Zhu G., Lancto C.A., et al. Complete genome sequence of the apicomplexan, Cryptosporidium parvum. Science 2004, 304:441-445.
2. Adams R.B., Guerrant R.L., Zu S., Fang G., Roche J.K. Cryptosporidium parvum infection of intestinal epithelium: morphologic and functional studies in an in vitro model. J. Infect. Dis. 1994, 169:170-177.
3. Aguero F., Al-Lazikani B., Aslett M., Berriman M., Buckner F.S., Campbell R.K., et al. Genomic-scale prioritization of drug targets: the TDR targets database. Nat. Rev. Drug Discov. 2008, 7:900-907.
4. Alves M., Matos O., Pereira Da Fonseca I., Delgado E., Lourenco A.M., Antunes F. Multilocus genotyping of Cryptosporidium isolates from human HIV-infected and animal hosts. J. Eukaryot. Microbiol. 2001, Suppl:17S-18S.
5. Alves M., Xiao L., Sulaiman I., Lal A.A., Matos O., Antunes F. Subgenotype analysis of Cryptosporidium isolates from humans, cattle, and zoo ruminants in Portugal. J. Clin. Microbiol. 2003, 41:2744-2747.
6. Alves M., Xiao L., Antunes F., Matos O. Distribution of Cryptosporidium subtypes in humans and domestic and wild ruminants in Portugal. Parasitol. Res. 2006, 99:287-292.
7. Amadi B., Kelly P., Mwiya M., Mulwazi E., Sianongo S., Changwe F., et al. Intestinal and systemic infection, HIV, and mortality in Zambian children with persistent diarrhea and malnutrition. J. Pediatr. Gastroenterol. Nutr. 2001, 32:550-554.
8. Amadi B., Mwiya M., Musuku J., Watuka A., Sianongo S., Ayoub A., et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 2002, 360:1375-1380.
9. Amin N.M. Prophylaxis for malaria. Helping world travelers come home healthy. Postgrad. Med. 1992, 92:161-168.
10. Anonymous United States Public Health Service/Infectious Disease Society of America guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Morb. Mortal. Wkly Rep. 2002, 51:1-46.
11. Anonymous World Health Report 2004: Changing History 2004, World Health Organization, Geneva, (p. 96).
12. Anonymous Preventing person-to-person spread following gastrointestinal infections: guidelines for public health physicians and environmental health officers. Commun. Dis. Public Health 2004, 7:362-384.
13. Arenas-Pinto A., Certad G., Ferrara G., Castro J., Bello M.A., Nunez L.T. Association between parasitic intestinal infections and acute or chronic diarrhoea in HIV-infected patients in Caracas, Venezuela. Int. J. STD. AIDS 2003, 14:487-492.
14. Argenzio R.A., Liacos J.A., Levy M.L., Meuten D.J., Lecce J.G., Powell D.W. Villous atrophy, crypt hyperplasia, cellular infiltration, and impaired glucose-Na absorption in enteric cryptosporidiosis of pigs. Gastroenterol. 1990, 98:1129-1140.
15. Armson A., Thompson R.C., Reynoldson J.A. A review of chemotherapeutic approaches to the treatment of cryptosporidiosis. Expert Rev. Anti Infect. Ther. 2003, 1:297-305.
16. Arrowood M.J. In vitro cultivation of Cryptosporidium species. Clin. Microbiol. Rev. 2002, 15:390-400.
17. Balda M.S., Anderson J.M. Two classes of tight junctions are revealed by Zo-1 isoforms. Am. J. Physiol. 1993, 264:C918-C924.
18. Barnes D.A., Bonnin A., Huang J.X., Gousset L., Wu J., Gut J., et al. A novel multi-domain mucin-like glycoprotein of Cryptosporidium parvum mediates invasion. Mol. Biochem. Parasitol. 1998, 96:93-110.
19. Barrias E.S., Reignault L.C., De Souza W., Carvalho T.M. Dynasore, a dynamin inhibitor, inhibits Trypanosoma cruzi entry into peritoneal macrophages. PLoS One 2010, 5:e7764.
20. Biggs B.A., Megna R., Wickremesinghe S., Dwyer B. Human infection with Cryptosporidium spp.: results of a 24-month survey. Med. J. Aust. 1987, 147:175-177.
21. Blagburn B.L., Lindsay D.S., Giambrone J.J., Sundermann C.A., Hoerr F.J. Experimental cryptosporidiosis in broiler chickens. Poult. Sci. 1987, 66:442-449.
22. Blanshard C., Jackson A.M., Shanson D.C., Francis N., Gazzard B.G. Cryptosporidiosis in HIV seropositive patients. Q. J. Med. 1992, 85:813-823.
23. Bonacini M. Hepatobiliary complications in patients with human immunodeficiency virus infection. Am. J. Med. 1992, 92:404-411.
24. Bonnin A., Ojcius D.M., Souque P., Barnes D.A., Doyle P.S., Gut J., et al. Characterization of a monoclonal antibody reacting with antigen-4 domain of gp900 in Cryptosporidium parvum invasive stages. Parasitol. Res. 2001, 87:589-592.
25. Boulter-Bitzer J.I., Lee H., Trevors J.T. Molecular targets for detection and immunotherapy in Cryptosporidium parvum. Biotechnol. Adv. 2007, 25:13-44.
26. Buret A.G., Chin A.C., Scott K.G. Infection of human and bovine epithelial cells with Cryptosporidium andersoni induces apoptosis and disrupts tight junctional ZO-1: effects of epidermal growth factor. Int. J. Parasitol. 2003, 33:1363-1371.
27. Burtt N.P. Whole-genome amplification using Φ29 DNA polymerase. Cold Spring Harb. Protoc. 2011, 1. epub 2011/01/06.
28. Cacciò S.M. Molecular epidemiology of human cryptosporidiosis. Parassitologia 2005, 47:185-192.
29. Cacciò S.M., Pozio E. Advances in the epidemiology, diagnosis and treatment of cryptosporidiosis. Expert. Rev. Anti. Infect. Ther. 2006, 4:429-443.
30. Cacciò S., Homan W., Camilli R., Traldi G., Kortbeek T., Pozio E. A microsatellite marker reveals population heterogeneity within human and animal genotypes of Cryptosporidium parvum. Parasitology 2000, 120(Pt 3):237-244.
31. Cacciò S., Spano F., Pozio E. Large sequence variation at two microsatellite loci among zoonotic (genotype C) isolates of Cryptosporidium parvum. Int. J. Parasitol. 2001, 31:1082-1086.
32. Caldas L.A., Attias M., de Souza W. Dynamin inhibitor impairs Toxoplasma gondii invasion. FEMS Microbiol. Lett. 2009, 301:103-108.
33. Cama V.A., Marshall M.M., Shubitz L.F., Ortega Y.R., Sterling C.R. Treatment of acute and chronic Cryptosporidium parvum infections in mice using clarithromycin and 14-OH clarithromycin. J. Eukaryot. Microbiol. 1994, 41:25S.
34. Cama V.A., Ross J.M., Crawford S., Kawai V., Chavez-Valdez R., Vargas D., et al. Differences in clinical manifestations among Cryptosporidium species and subtypes in HIV-infected persons. J. Infect. Dis. 2007, 196:684-691.
35. Cama V.A., Bern C., Roberts J., Cabrera L., Sterling C.R., Ortega Y., et al. Cryptosporidium species and subtypes and clinical manifestations in children, Peru. Emerg. Infect. Dis. 2008, 14:1567-1574.
36. Campbell B.E., Hofmann A., McCluskey A., Gasser R.B. Serine/threonine phosphatases in socioeconomically important parasitic nematodes-prospects as novel drug targets?. Biotechnol. Adv. 2010, 29:28-39.
37. Cappell M.S., Hassan T. Pancreatic disease in AIDS-a review. J. Clin. Gastroenterol. 1993, 17:254-263.
38. Casemore D.P. The antibody response to Cryptosporidium: development of a serological test and its use in a study of immunologically normal persons. J. Infect. 1987, 14:125-134.
39. Certad G., Arenas-Pinto A., Pocaterra L., Ferrara G., Castro J., Bello A., et al. Cryptosporidiosis in HIV-infected Venezuelan adults is strongly associated with acute or chronic diarrhea. Am. J. Trop. Med. Hyg. 2005, 73:54-57.
40. Cevallos A.M., Bhat N., Verdon R., Hamer D.H., Stein B., Tzipori S., et al. Mediation of Cryptosporidium parvum infection in vitro by mucin-like glycoproteins defined by a neutralizing monoclonal antibody. Infect. Immun. 2000, 68:5167-5175.
41. Chalmers R.M., Elwin K., Thomas A.L., Joynson D.H. Infection with unusual types of Cryptosporidium is not restricted to immunocompromised patients. J. Infect. Dis. 2002, 185:270-271.
42. Chang A., Scheer M., Grote A., Schomburg I., Schomburg D. BRENDA, AMENDA and FRENDA the enzyme information system: new content and tools in 2009. Nucleic Acids Res. 2009, 37:D588-D592.
43. Chappell C.L., Okhuysen P.C., Sterling C.R., DuPont H.L. Cryptosporidium parvum: intensity of infection and oocyst excretion patterns in healthy volunteers. J. Infect. Dis. 1996, 173:232-236.
44. Chaudhary K., Roos D.S. Protozoan genomics for drug discovery. Nat. Biotechnol. 2005, 23:1089-1091.
45. Checkley W., Gilman R.H., Epstein L.D., Suarez M., Diaz J.F., Cabrera L., et al. Asymptomatic and symptomatic cryptosporidiosis: their acute effect on weight gain in Peruvian children. Am. J. Epidemiol. 1997, 145:156-163.
46. Chen X.M., Levine S.A., Tietz P., Krueger E., McNiven M.A., Jefferson D.M., et al. Cryptosporidium parvum is cytopathic for cultured human biliary epithelia via an apoptotic mechanism. Hepatology 1998, 28:906-913.
47. Chen X.M., Gores G.J., Paya C.V., LaRusso N.F. Cryptosporidium parvum induces apoptosis in biliary epithelia by a Fas/Fas ligand-dependent mechanism. Am. J. Physiol. 1999, 277:G599-G608.
48. Chhin S., Harwell J.I., Bell J.D., Rozycki G., Ellman T., Barnett J.M., et al. Etiology of chronic diarrhea in antiretroviral-naive patients with HIV infection admitted to Norodom Sihanouk Hospital, Phnom Penh, Cambodia. Clin. Infect. Dis. 2006, 43:925-932.
49. Clavel A., Arnal A.C., Sanchez E.C., Cuesta J., Letona S., Amiguet J.A., et al. Respiratory cryptosporidiosis: case series and review of the literature. Infection 1996, 24:341-346.
50. Colford J.M., Tager I.B., Hirozawa A.M., Lemp G.F., Aragon T., Petersen C. Cryptosporidiosis among patients infected with human immunodeficiency virus, factors related to symptomatic infection and survival. Am. J. Epidemiol. 1996, 144:807-816.
51. Crowther G.J., Shanmugam D., Carmona S.J., Doyle M.A., Hertz-Fowler C., Berriman M., et al. Identification of attractive drug targets in neglected-disease pathogens using an in silico approach. PLoS Negl. Trop. Dis. 2010, 4:e804.
52. Current W.L., Haynes T.B. Complete development of Cryptosporidium in cell culture. Science 1984, 224:603-605.
53. Current W.L., Long P.L. Development of human and calf Cryptosporidium in chicken embryos. J. Infect. Dis. 1983, 148:1108-1113.
54. Current W.L., Owen R.L. Cryptosporidiosis and microsporidiosis. Enteric Infection: Mechanisms, Manifestations and Management 1989, 223-249. Chapman Hall, London, UK. M.J.G. Farthing, G.T. Keusch (Eds.).
55. Current W.L., Reese N.C., Ernst J.V., Bailey W.S., Heyman M.B., Weinstein W.M. Human cryptosporidiosis in immunocompetent and immunodeficient persons. Studies of an outbreak and experimental transmission. N. Engl. J. Med. 1983, 308:1252-1257.
56. de Beer T.A., Wells G.A., Burger P.B., Joubert F., Marechal E., Birkholtz L., et al. Antimalarial drug discovery: in silico structural biology and rational drug design. Infect. Disord. Drug Targets 2009, 9:304-318.
57. Deng M., Rutherford M.S., Abrahamsen M.S. Host intestinal epithelial response to Cryptosporidium parvum. Adv. Drug Deliv. Rev. 2004, 56:869-884.
58. Dolmatch B.L., Laing F.C., Ferderle M.P., Jeffrey R.B., Cello J. AIDS-related cholangitis: radiographic findings in nine patients. Radiology 1987, 163:313-316.
59. Dowsett J.F., Miller R., Davidson R., Vaira D., Polydorou A., Cairns S.R., et al. Sclerosing cholangitis in acquired immunodeficiency syndrome. Case reports and review of the literature. Scand. J. Gastroenterol. 1988, 23:1267-1274.
60. Doyle M.A., Gasser R.B., Woodcroft B.J., Hall R.S., Ralph S.A. Drug target prediction and prioritization: using orthology to predict essentiality in parasite genomes. BMC Genomics 2010, 11:222.
61. Edwards P., Wodak A., Cooper D.A., Thompson I.L., Penny R. The gastrointestinal manifestations of AIDS. Aust. N. Z. J. Med. 1990, 20:141-148.
62. Elliott D.A., Coleman D.J., Lane M.A., May R.C., Machesky L.M., Clark D.P. Cryptosporidium parvum infection requires host cell actin polymerization. Infect. Immun. 2001, 69:5940-5942.
63. Elsser K.A., Moricz M., Proctor E.M. Cryptosporidium infections: a laboratory survey. Can. Med. Assoc. J. 1986, 135:211-213.
64. Fairhurst R.M. Transgenic parasites: improving our understanding of innate immunity to malaria. Cell Host Microbe 2007, 2:75-76.
65. Fanning A.S., Jameson B.J., Jesaitis L.A., Anderson J.M. The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J. Biol. Chem. 1998, 273:29745-29753.
66. Fayer R. Cryptosporidium: a water-borne zoonotic parasite. Vet. Parasitol. 2004, 126:37-56.
67. Fayer R., Morgan U.M., Upton S.J. Epidemiology of Cryptosporidium: transmission, detection and identification. Int. J. Parasitol. 2000, 30:1305-1322.
68. Fiocchi C. Inflammatory bowel disease etiology and pathogenesis. Gastroenterol. 1998, 115:182-205.
69. Flanigan T., Whalen C., Turner J., Soave R., Toerner J., Havlir D., et al. Cryptosporidium infection and CD4 counts. Ann. Intern. Med. 1992, 116:840-842.
70. Forbes A., Blanshard C., Gazzard B. Natural history of AIDS related schlerosing cholangitis: a study of 20 cases. Gut 1993, 34:116-121.
71. Forney J.R., Vaughan D.K., Yang S., Healey M.C. Actin-dependent motility in Cryptosporidium parvum sporozoites. J. Parasitol. 1998, 84:908-913.
72. Gardner M.J., Hall N., Fung E., White O., Berriman M., Hyman R.W., et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002, 419:498-511.
73. Giangaspero A., Iorio R., Paoletti B., Traversa D., Capelli G. Molecular evidence for Cryptosporidium infection in dogs in Central Italy. Parasitol. Res. 2006, 99:297-299.
74. Giles M., Webster K.A., Marshall J.A., Catchpole J., Goddard T.M. Experimental infection of a lamb with Cryptosporidium parvum genotype 1. Vet. Rec. 2001, 149:523-525.
75. Girouard D., Gallant J., Akiyoshi D.E., Nunnari J., Tzipori S. Failure to propagate Cryptosporidium spp. in cell-free culture. J. Parasitol. 2006, 92:399-400.
76. Gomez Morales M.A., Pozio E. Humoral and cellular immunity against Cryptosporidium infection. Curr. Drug Targets Immune Endocr. Metabol. Disord. 2002, 2:291-301.
77. Goodgame R.W., Genta R.M., White A.C., Chappell C.L. Intensity of infection in AIDS-associated cryptosporidiosis. J. Infect. Dis. 1993, 167:704-709.
78. Goodwin T.A. Cryptosporidiosis in the acquired immunodeficiency syndrome: a study of 15 autopsy cases. Hum. Pathol. 1991, 22:1215-1224.
79. Griffiths J.K., Moore R., Dooley S., Keusch G.T., Tzipori S. Cryptosporidium parvum infection of Caco-2 cell monolayers induces an apical monolayer defect, selectively increases transmonolayer permeability, and causes epithelial cell death. Infect. Immun. 1994, 62:4506-4514.
80. Guarino A., Canani R.B., Pozio E., Terracciano L., Albano F., Mazzeo M. Enterotoxic effect of stool supernatant of Cryptosporidium-infected calves on human jejunum. Gastroenterol. 1994, 106:28-34.
81. Guarino A., Canani R.B., Casola A., Pozio E., Russo R., Bruzzese E., et al. Human intestinal cryptosporidiosis: secretory diarrhea and enterotoxic activity in Caco-2 cells. J. Infect. Dis. 1995, 171:976-983.
82. Guerrant D.I., Moore S.R., Lima A.A., Patrick P.D., Schorling J.B., Guerrant R.L. Association of early childhood diarrhea and cryptosporidiosis with impaired physical fitness and cognitive function four-seven years later in a poor urban community in northeast Brazil. Am. J. Trop. Med. Hyg. 1999, 61:707-713.
83. Guthrie O.W. Aminoglycoside induced ototoxicity. Toxicology 2008, 249:91-96.
84. Hajdusek O., Ditrich O., Slapeta J. Molecular identification of Cryptosporidium spp. in animal and human hosts from the Czech Republic. Vet. Parasitol. 2004, 122:183-192.
85. Hatkin J.M., Lindsay D.S., Giambrone J.J., Hoerr F.J., Blagburn B.L. Experimental biliary cryptosporidiosis in broiler chickens. Avian Dis. 1990, 34:454-457.
86. Hayward A.R., Levy J., Facchetti F., Notarangelo L.D., Ochs H.D., Etzioni A., et al. Cholangiopathy and tumors of the pancreas, liver and biliary tree in boys with X-linked immunodeficiency with hyper-IgM (XHIM). J. Immunol. 1997, 158:157-167.
87. Hellard M.E., Sinclair M.I., Hogg G.G., Fairley C.K. Prevalence of enteric pathogens among community based asymptomatic individuals. J. Gastroenterol. Hepatol. 2000, 15:290-293.
88. Hernandez J., Lackner A., Aye P., Mukherjee K., Tweardy D.J., Mastrangelo M.A., et al. Substance p is responsible for physiological alterations such as increased chloride ion secretion and glucose malabsorption in cryptosporidiosis. Infect. Immun. 2007, 75:1137-1143.
89. Hewitt R.G., Yiannoutsos C.T., Higgs E.S., Carey J.T., Geiseler P.J., Soave R., et al. Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trial Group. Clin. Infect. Dis. 2000, 31:1084-1092.
90. Hijjawi N. Cryptosporidium: new developments in cell culture. Exp. Parasitol. 2010, 124:54-60.
91. Hijjawi N.S., Meloni B.P., Morgan U.M., Thompson R.C.A. Complete development and long-term maintenance of Cryptosporidium parvum human and cattle genotype in cell culture. Int. J. Parasitol. 2001, 31:1048-1055.
92. Hijjawi N.S., Meloni B.P., Ng'anzo M., Ryan U., Olson M.E., Cox P.T., et al. Complete development of Cryptosporidium parvum in host cell-free culture. Int. J. Parasitol. 2004, 34:769-777.
93. Hijjawi N., Estcourt A., Yang R., Monis P., Ryan U. Complete development and multiplication of Cryptosporidium hominis in cell-free culture. Vet. Parasitol. 2010, 169:29-36.
94. Avoiding Ill Health at Open Farms: Advice to Farmers (With Teachers' Supplement) 2000, HSE, HES Books, London, UK, p. 5.
95. Common zoonoses in agriculture 2000, HSE, HSE Books, London, UK, p. 6.
96. Huh J.G., Kim Y.S., Lee J.S., Jeong T.Y., Ryu S.H., Lee J.H., et al. Mycobacterium ulcerans infection as a cause of chronic diarrhea in an AIDS patient: a case report. World J. Gastroenterol. 2008, 14:808-811.
97. Hunter P.R., Thompson R.C. The zoonotic transmission of Giardia and Cryptosporidium. Int. J. Parasitol. 2005, 35:1181-1190.
98. Inman L.R., Takeuchi A. Spontaneous cryptosporidiosis in an adult female rabbit. Vet. Pathol. 1979, 16:89-95.
99. Jakobi V., Petry F. Differential expression of Cryptosporidium parvum genes encoding sporozoite surface antigens in infected HCT-8 host cells. Microbes Infect. 2006, 8:2186-2194.
100. Jex A.R., Gasser R.B. Diagnostic and analytical mutation scanning of Cryptosporidium-utility and advantages. Exp. Rev. Mol. Diagn. 2009, 9:179-186.
101. Jex A.R., Gasser R.B. Genetic richness and diversity in Cryptosporidium hominis and C. parvum reveals major knowledge gaps and a need for the application of "next generation" technologies-Research review. Biotechnol. Adv. 2010, 26:17-26.
102. Jex A.R., Pangasa A., Campbell B.E., Whipp M., Hogg G., Sinclair M.I., et al. Classification of Cryptosporidium species from patients with sporadic cryptosporidiosis by use of sequence-based multilocus analysis following mutation scanning. J. Clin. Microbiol. 2008, 46:2252-2262.
103. Jex A.R., Chalmers R., Smith H.V., Widmer G., McDonald V., Gasser R.B. Cryptospordiosis. Oxford textbook of zoonoses: Biology, clinical practice, and public health control 2010, 536-538. Oxford Textbooks in Public Health, Oxford University Press, Oxford. Palmer, Soulsby, Torgerson, Brown (Eds.).
104. Jeyanthi T., Subramanian P. Nephroprotective effect of Withania somnifera: a dose-dependent study. Ren. Fail. 2009, 31:814-821.
105. Jokipii L., Jokipii A.M. Timing of symptoms and oocyst excretion in human cryptosporidiosis. N. Engl. J. Med. 1986, 315:1643-1647.
106. Jokipii L., Pohjola S., Jokipii A.M. Cryptosporidium: a frequent finding in patients with gastrointestinal symptoms. Lancet 1983, 2:358-361.
107. Kapel N., Huneau J.F., Magne D., Tome D., Gobert J.G. Cryptosporidiosis-induced impairment of ion transport and Na+-glucose absorption in adult immunocompromised mice. J. Infect. Dis. 1997, 176:834-837.
108. Karanis P., Kourenti C., Smith H. Waterborne transmission of protozoan parasites: a worldwide review of outbreaks and lessons learnt. J. Water Health 2007, 5:1-38.
109. Karanis P., Kimura A., Nagasawa H., Igarashi I., Suzuki N. Observations on Cryptosporidium life cycle stages during excystation. J. Parasitol. 2008, 94:298-300.
110. Kaye D. CDC says there are ways to reduce enteric pathogen transmission in swimming pools. Clin. Infect. Dis. 2001, 33:i.
111. Kocken C.H., Zeeman A.M., Voorberg-van der Wel A., Thomas A.W. Transgenic Plasmodium knowlesi: relieving a bottleneck in malaria research?. Trends Parasitol. 2009, 25:370-374.
112. Korich D.G., Mead J.R., Madore M.S., Sinclair N.A., Sterling C.R. Effects of ozone, chlorine dioxide, chlorine, and monochloramine on Cryptosporidium parvum oocyst viability. Appl. Environ. Microbiol. 1990, 56:1423-1428.
113. Kosek M., Alcantara C., Lima A.A., Guerrant R.L. Cryptosporidiosis: an update. Lancet Infect. Dis. 2001, 1:262-269.
114. Lacharme L., Villar V., Rojo-Vazquez F.A., Suarez S. Complete development of Cryptosporidium parvum in rabbit chondrocytes (VELI cells). Microbes Infect. 2004, 6:566-571.
115. Lacroix C., Berthier M., Agius G., Bonneau D., Pallu B., Jacquemin J.L. Cryptosporidium oocysts in immunocompetent children: epidemiologic investigations in the day-care centers of Poitiers, France. Eur. J. Epidemiol. 1987, 3:381-385.
116. Lally N.C., Baird G.D., McQuay S.J., Wright F., Oliver J.J. A 2359-base pair DNA fragment from Cryptosporidium parvum encoding a repetitive oocyst protein. Mol. Biochem. Parasitol. 1992, 56:69-78.
117. Lau H., Ferlan J.T., Brophy V.H., Rosowsky A., Sibley C.H. Efficacies of lipophilic inhibitors of dihydrofolate reductase against parasitic protozoa. Antimicrob. Agents Chemother. 2001, 45:187-195.
118. Lazar L., Radulescu S. Cryptosporidiosis in children and adults: parasitological and clinico-epidemiological features. Arch. Roum. Pathol. Exp. Microbiol. 1989, 48:357-365.
119. Lazzari R., Collina A., Vallini M., Corvaglia L., Lomio G., Aurelio F. Chronic diarrhea due to Cryptosporidium in an immunocompetent subject. Pediatr. Med. Chir. 1991, 13:643-644.
120. Lebbad M., Norrgren H., Naucler A., Dias F., Andersson S., Linder E. Intestinal parasites in HIV-2 associated AIDS cases with chronic diarrhoea in Guinea-Bissau. Acta Trop. 2001, 80:45-49.
121. Lemeteil D., Roussel F., Favennec L., Ballet J.J., Brasseur P. Assessment of candidate anticryptosporidial agents in an immunosuppressed rat model. J. Infect. Dis. 1993, 167:766-768.
122. Leoni F., Amar C., Nichols G., Pedraza-Diaz S., McLauchlin J. Genetic analysis of Cryptosporidium from 2414 humans with diarrhoea in England between 1985 and 2000. J. Med. Microbiol. 2006, 55:703-707.
123. Lim Y.A.L., Jex A.R., Smith H.V., Gasser R.B. Cryptosporidiosis in Southeast Asia: what's out there?. Adv. Parasitol. 2010, 71:1-31.
124. Lindsay D.S., Blagburn B.L., Sundermann C.A., Ernest J.A. Chemoprophylaxis of cryptosporidiosis in chickens, using halofuginone, salinomycin, lasalocid, or monensin. Am. J. Vet. Res. 1987, 48:354-355.
125. Lipinski C.A. Drug-like properties and the causes of poor solubility and permeability. J. Pharmacol. Toxicol. Methods 2001, 44:235-249.
126. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and dermeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 1997, 23:3-25.
127. Lumadue J.A., Manabe Y.C., Moore R.D., Belitsos P.C., Sears C.L., Clark D.P. A clinicopathologic analysis of AIDS-related cryptosporidiosis. AIDS 1998, 12:2459-2466.
128. Martinez-Salgado C., Lopez-Hernandez F.J., Lopez-Novoa J.M. Glomerular nephrotoxicity of aminoglycosides. Toxicol. Appl. Pharmacol. 2007, 223:86-98.
129. Masuno K., Yanai T., Hirata A., Yonemaru K., Sakai H., Satoh M., et al. Morphological and immunohistochemical features of Cryptosporidium andersoni in cattle. Vet. Pathol. 2006, 43:202-207.
130. Matsubayashi M., Abe N., Takami K., Kimata I., Iseki M., Nakanishi T., et al. First record of Cryptosporidium infection in a raccoon dog (Nyctereutes procyonoides viverrinus). Vet. Parasitol. 2004, 120:171-175.
131. Mita T. Origins and spread of pfdhfr mutant alleles in Plasmodium falciparum. Acta Trop. 2010, 114:166-170.
132. Mita T., Tanabe K., Kita K. Spread and evolution of Plasmodium falciparum drug resistance. Parasitol. Int. 2009, 58:201-209.
133. Morgan U.M., Sargent K.D., Deplazes P., Forbes D.A., Spano F., Hertzberg H., et al. Molecular characterization of Cryptosporidium from various hosts. Parasitology 1998, 117:31-37.
134. Morgan U.M., Xiao L., Hill B.D., O'Donoghue P., Limor J., Lal A., et al. Detection of the Cryptosporidium parvum "human" genotype in a dugong (Dugong dugon). J. Parasitol. 2000, 86:1352-1354.
135. Morgan-Ryan U.M., Fall A., Ward L.A., Hijjawi N., Sulaiman I., Fayer R., et al. Cryptosporidium hominis n. sp. (Apicomplexa: Cryptosporidiidae) from Homo sapiens. J. Eukaryot. Microbiol. 2002, 49:433-440.
136. Murakami S., Nagai J., Fujii K., Yumoto R., Takano M. Influences of dosage regimen and co-administration of low-molecular weight proteins and basic peptides on renal accumulation of arbekacin in mice. J. Antimicrob. Chemother. 2008, 61:658-664.
137. Mwachari C., Batchelor B.I., Paul J., Waiyaki P.G., Gilks C.F. Chronic diarrhoea among HIV-infected adult patients in Nairobi, Kenya. J. Infect. 1998, 37:48-53.
138. Nagai J., Takano M. Molecular-targeted approaches to reduce renal accumulation of nephrotoxic drugs. Exp. Opin. Drug Metab. Toxicol. 2010, 6:1125-1138.
139. Okhuysen P.C., Chappell C.L., Crabb J.H., Sterling C.R., DuPont H.L. Virulence of three distinct Cryptosporidium parvum isolates for healthy adults. J. Infect. Dis. 1999, 180:1275-1281.
140. Ortega-Pierres G., Smith H.V., Cacciò S.M., Thompson R.C. New tools provide further insights into Giardia and Cryptosporidium biology. Trends Parasitol. 2009, 25:410-416.
141. Palmieri F., Cicalini S., Froio N., Rizzi E.B., Goletti D., Festa A., et al. Pulmonary cryptosporidiosis in an AIDS patient: successful treatment with paromomycin plus azithromycin. Int. J. STD AIDS 2005, 16:515-517.
142. Pannu N., Nadim M.K. An overview of drug-induced acute kidney injury. Crit. Care Med. 2008, 36:S216-S223.
143. Peeters J.E., Mazas E.A., Masschelein W.J., Martiez Villacorta, de Maturana I., Debacker E. Effect of disinfection of drinking water with ozone or chlorine dioxide on survival of Cryptosporidium parvum oocysts. Appl. Environ. Microbiol. 1989, 55:1519-1522.
144. Petry F., Kneib I., Harris J.R. Morphology and in vitro infectivity of sporozoites of Cryptosporidium parvum. J. Parasitol. 2009, 95:1243-1246.
145. PHLSSG Cryptosporidiosis in England and Wales: prevalence and clinical and epidemiological features. Public Health Laboratory Service Study Group. Brit. Med. J 1990, 300:774-777.
146. Pinard R., de Winter A., Sarkis G.J., Gerstein M.B., Tartaro K.R., Plant R.N., et al. Assessment of whole genome amplification-induced bias through high-throughput, massively parallel whole genome sequencing. BMC Genomics 2006, 7:216.
147. Portnoy D., Whiteside M.E., Buckley E., MacLeod C.L. Treatment of intestinal cryptosporidiosis with spiramycin. Ann. Intern. Med. 1984, 101:202-204.
148. Putignani L., Menichella D. Global distribution, public health and clinical impact of the protozoan pathogen Cryptosporidium. Interdiscip. Perspect. Infect. Dis. 2010, (2010, pii: 753512. Epub 2010 Jul 14).
149. Rey P., Carrere C., Casassus-Builhe D., Perret J.L. Chronic diarrhea induced by Cryptosporidium parvum in an immunocompetent adult: difficult diagnosis and unsatisfactory treatment. Gastroenterol. Clin. Biol. 2004, 28:501-502.
150. Ricci K.A., Girosi F., Tarr P.I., Lim Y.-W., Mason C., Miller M., et al. Reducing stunting among children: the potential contribution of diagnostics. Nature 2006, 444:29-38. 10.1038/nature05443.
151. Riggs M.W. Recent advances in cryptosporidiosis: the immune response. Microbes Infect. 2002, 4:1067-1080.
152. Rivasi F., Rossi P., Righi E., Pozio E. Gastric cryptosporidiosis: correlation between intensity of infection and histological alterations. Histopathology 1999, 34:405-409.
153. Rizzi M.D., Hirose K. Aminoglycoside ototoxicity. Curr. Opin. Otolaryngol. Head Neck Surg. 2007, 15:352-357.
154. Roberts F., Roberts C.W., Johnson J.J., Kyle D.E., Krell T., Coggins J.R., et al. Evidence for the shikimate pathway in apicomplexan parasites. Nature 1998, 393:801-805.
155. Robertson L.J. Giardia and Cryptosporidium infections in sheep and goats: a review of the potential for transmission to humans via environmental contamination. Epidemiol. Infect. 2009, 137:913-921.
156. Robinson P., Okhuysen P.C., Chappell C.L., Weinstock J.V., Lewis D.E., Actor J.K., et al. Substance P expression correlates with severity of diarrhea in cryptosporidiosis. J. Infect. Dis. 2003, 188:290-296.
157. Rosenblatt J.E. Antiparasitic agents. Mayo Clin. Proc. 1992, 67:276-287.
158. Rosenthal P.J. Proteases of protozoan parasites. Adv. Parasitol. 1999, 43:105-159.
159. Rossignol J.F. Nitazoxanide in the treatment of acquired immune deficiency syndrome-related cryptosporidiosis: results of the United States compassionate use program in 365 patients. Aliment. Pharmacol. Ther. 2006, 24:887-894.
160. Rossignol J.F., Ayoub A., Ayers M.S. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide. J. Infect. Dis. 2001, 184:103-106.
161. Ryan U., Read C., Hawkins P., Warnecke M., Swanson P., Griffith M., et al. Genotypes of Cryptosporidium from Sydney water catchment areas. J. Appl. Microbiol. 2005, 98:1221-1229.
162. Ryan U.M., Bath C., Robertson I., Read C., Elliot A., McInnes L., et al. Sheep may not be an important zoonotic reservoir for Cryptosporidium and Giardia parasites. Appl. Environ. Microbiol. 2005, 71:4992-4997.
163. Saez-Llorens X., Odio C.M., Umana M.A., Morales M.V. Spiramycin vs. placebo for treatment of acute diarrhea caused by Cryptosporidium. Pediatr. Infect. Dis. J. 1989, 8:136-140.
164. Santin M., Trout J.M., Fayer R. Prevalence and molecular characterization of Cryptosporidium and Giardia species and genotypes in sheep in Maryland. Vet. Parasitol. 2007, 146:17-24.
165. Savioli L., Smith H., Thompson A. Giardia and Cryptosporidium join the 'Neglected Diseases Initiative'. Trends Parasitol. 2006, 22:203-208.
166. Saxena N., Lahiri S.S., Hambarde S., Tripathi R.P. RAS: target for cancer therapy. Cancer Invest. 2008, 26:948-955.
167. Scaglia M., Gatti S., Bassi P., Viale P.L., Novati S., Ranieri S. Intestinal co-infection by Cyclospora sp. and Cryptosporidium parvum: first report in an AIDS patient. Parasite 1994, 1:387-390.
168. Schneidman-Duhovny D., Inbar Y., Nussinov R., Wolfson H.J. PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res. 2005, 33:W363-W367.
169. Schomburg I., Chang A., Schomburg D. BRENDA, enzyme data and metabolic information. Nucleic Acids Res. 2002, 30:47-49.
170. Shirley M. The genome of Eimeria tenella: further studies on its molecular organisation. Parasitol. Res. 1994, 80:366-373.
171. Shirley M.W. The genome of Eimeria spp., with special reference to Eimeria tenella-a coccidium from the chicken. Int. J. Parasitol. 2000, 30:485-493.
172. Siefker C., Rickard L.G., Pharr G.T., Simmons J.S., O'Hara T.M. Molecular characterization of Cryptosporidium sp. isolated from northern Alaskan caribou (Rangifer tarandus). J. Parasitol. 2002, 88:213-216.
173. Sifuentes L.Y., Di Giovanni G.D. Aged HCT-8 Cell monolayers support Cryptosporidium parvum infection. Appl. Environ. Microbiol. 2007, 73:7548-7551.
174. Sirichaiwat C., Intaraudom C., Kamchonwongpaisan S., Vanichtanankul J., Thebtaranonth Y., Yuthavong Y. Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum. J. Med. Chem. 2004, 47:345-354.
175. Smith H.V., Corcoran G.D. New drugs and treatment for cryptosporidiosis. Curr. Opin. Infect. Dis. 2004, 17:557-564.
176. Smith H., Nichols R.A. Zoonotic protozoa-food for thought. Parassitologia 2006, 48:101-104.
177. Smith H.V., Nichols R.A., Grimason A.M. Cryptosporidium excystation and invasion: getting to the guts of the matter. Trends Parasitol. 2005, 21:133-142.
178. Smith H.V., Nichols R.A., Mallon M., Macleod A., Tait A., Reilly W.J., et al. Natural Cryptosporidium hominis infections in Scottish cattle. Vet. Rec. 2005, 156:710-711.
179. Soave R., Armstrong D. Cryptosporidium and cryptosporidiosis. Rev. Infect. Dis. 1986, 8:1012-1023.
180. Soave R., Johnson W.D. AIDS commentary. Cryptosporidium and Isospora belli infections. J. Infect. Dis. 1998, 157:225-229.
181. Sonea I.M., Palmer M.V., Akili D., Harp J.A. Treatment with neurokinin-1 receptor antagonist reduces severity of inflammatory bowel disease induced by Cryptosporidium parvum. Clin. Diagn. Lab. Immunol. 2002, 9:333-340.
182. Sorensen K.M., Jespersgaard C., Vuust J., Hougaard D., Norgaard-Pedersen B., Andersen P.S. Whole genome amplification on DNA from filter paper blood spot samples: an evaluation of selected systems. Genet. Test. 2007, 11:65-71.
183. Spano F., Putignani L., Naitza S., Puri C., Wright S., Crisanti A. Molecular cloning and expression analysis of a Cryptosporidium parvum gene encoding a new member of the thrombospondin family. Mol. Biochem. Parasitol. 1998, 92:147-162.
184. Sprinz E., Mallman R., Barcellos S., Silbert S., Schestatsky G., Bem David D. AIDS-related cryptosporidial diarrhoea: an open study with roxithromycin. J. Antimicrob. Chemother. 1998, 41(Suppl. B):85-91.
185. Starkey S.R., Wade S.E., Schaaf S., Mohammed H.O. Incidence of Cryptosporidium parvum in the dairy cattle population in a New York City Watershed. Vet. Parasitol. 2005, 131:197-205.
186. Striepen B., Pruijssers A.J., Huang J., Li C., Gubbels M.J., Umejiego N.N., et al. Gene transfer in the evolution of parasite nucleotide biosynthesis. Proc. Natl. Acad. Sci. USA 2004, 101:3154-3159.
187. Strong W.B., Gut J., Nelson R.G. Cloning and sequence analysis of a highly polymorphic Cryptosporidium parvum gene encoding a 60-kilodalton glycoprotein and characterization of its 15- and 45-kilodalton zoite surface antigen products. Infect. Immun. 2000, 68:4117-4134.
188. Sun T., Teichberg S. Protozoal infections in the acquired immunodeficiency syndrome. J. Electron Microsc. Tech. 1988, 8:79-103.
189. Talisuna A.O., Okello P.E., Erhart A., Coosemans M., D'Alessandro U. Intensity of malaria transmission and the spread of Plasmodium falciparum resistant malaria: a review of epidemiologic field evidence. Am. J. Trop. Med. Hyg. 2007, 77:170-180.
190. Taylor P., Blackburn E., Sheng Y.G., Harding S., Hsin K.Y., Kan D., et al. Ligand discovery and virtual screening using the program LIDAEUS. Br. J. Pharmacol. 2008, 153(Suppl. 1):S55-S67.
191. Teixidor H.S., Godwin T.A., Ramirez E.A. Cryptosporidiosis of the biliary tract in AIDS. Radiology 1991, 180:51-56.
192. Thomas E.K., Cancelas J.A., Zheng Y., Williams D.A. Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis. Leukemia 2008, 22:898-904.
193. Thomsen R., Christensen M.H. MolDock: a new technique for high-accuracy molecular docking. J. Med. Chem. 2006, 49:3315-3321.
194. Tugcu V., Ozbek E., Tasci A.I., Kemahli E., Somay A., Bas M., et al. Selective nuclear factor kappa-B inhibitors, pyrolidium dithiocarbamate and sulfasalazine, prevent the nephrotoxicity induced by gentamicin. Brit. J. Urol. Int. 2006, 98:680-686.
195. Tzipori S., Ward H. Cryptosporidiosis: biology, pathogenesis and disease. Microbes Infect. 2002, 4:1047-1058.
196. Tzipori S., Angus K.W., Campbell I., Clerihew L.W. Diarrhea due to Cryptosporidium infection in artificially reared lambs. J. Clin. Microbiol. 1981, 14:100-105.
197. Uip D.E., Lima A.L., Amato V.S., Boulos M., Neto V.A., Bem David D. Roxithromycin treatment for diarrhoea caused by Cryptosporidium spp. in patients with AIDS. J. Antimicrob. Chemother. 1998, 41(Suppl. 1):93-97.
198. Upcroft J.A., Upcroft P. Two distinct varieties of Giardia in a mixed infection from a single human patient. J. Eukaryot. Microbiol. 1994, 41:189-194.
199. Vakil N.B., Schwartz S.M., Buggy B.P., Brummitt C.F., Kherellah M., Letzer D.M., et al. Biliary cryptosporidiosis in HIV-infected people after the waterborne outbreak of cryptosporidiosis in Milwaukee. N. Engl. J. Med. 1996, 334:19-23.
200. Valigurová A., Jirku M., Koudela B., Gelnar M., Modrý D., Šlapeta J. Cryptosporidia: epicellular parasites embraced by the host cell membrane. Int. J. Parasitol. 2008, 38:913-922.
201. van de Waterbeemd H., Gifford E. ADMET in silico modelling: towards prediction paradise?. Nat. Rev. Drug Discov. 2003, 2:192-204.
202. Ventura G., Cauda R., Larocca L.M., Riccioni M.E., Tumbarello M., Lucia M.B. Gastric cryptosporidiosis complicating HIV infection: case report and review of the literature. Eur. J. Gastroenterol. Hepatol. 1997, 9:307-310.
203. Watkins W.M. Pharmacology and pharmacokinetics of new antimalarials. Med. Trop. (Mars). 1995, 55:33-36.
204. Welter B.H., Temesvari L.A. Overexpression of a mutant form of EhRabA, a unique Rab GTPase of Entamoeba histolytica, alters endoplasmic reticulum morphology and localization of the Gal/GalNAc adherence lectin. Eukaryot. Cell 2009, 8:1014-1026.
205. Westrope C., Acharya A. Diarrhea and gallbladder hydrops in an immunocompetent child with Cryptosporidium infection. Pediatr. Infect. Dis. J. 2001, 20:1179-1181.
206. Wetzel D.M., Schmidt J., Kuhlenschmidt M.S., Dubey J.P., Sibley L.D. Gliding motility leads to active cellular invasion by Cryptosporidium parvum sporozoites. Infect. Immun. 2005, 73:5379-5387.
207. Wieman H., Tondel K., Anderssen E., Drablos F. Homology-based modelling of targets for rational drug design. Mini Rev. Med. Chem. 2004, 4:793-804.
208. Williams D.A., Zheng Y., Cancelas J.A. Rho GTPases and regulation of hematopoietic stem cell localization. Methods Enzymol. 2008, 439:365-393.
209. Woods K.M., Upton S.J. In vitro development of Cryptosporidium parvum in serum-free media. Lett. Appl. Microbiol. 2007, 44:520-523.
210. Wu S.Y., McNae I., Kontopidis G., McClue S.J., McInnes C., Stewart K.J., et al. Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. Structure 2003, 11:399-410.
211. Wu L., Chen S.X., Jiang X.G., Shen Y.J., Lu Z.X., Tu G.H., et al. Effect of select medium supplements on in vitro development of Cryptosporidium andersoni in HCT-8 cells. Parasitol. Res. 2009, 105:1419-1424.
212. Xiao L., Feng Y. Zoonotic cryptosporidiosis. FEMS Immunol. Med. Microbiol. 2008, 52:309-323.
213. Xiao L., Ryan U.M. Cryptosporidiosis: an update in molecular epidemiology. Curr. Opin. Infect. Dis. 2004, 17:483-490.
214. Xiao L., Bern C., Limor J., Sulaiman I., Roberts J., Checkley W., et al. Identification of 5 types of Cryptosporidium parasites in children in Lima, Peru. J. Infect. Dis. 2001, 183:492-497.
215. Xiao L., Fayer R., Ryan U., Upton S.J. Cryptosporidium taxonomy: recent advances and implications for public health. Clin. Microbiol. Rev. 2004, 17:72-97.
216. Xu P., Widmer G., Wang Y., Ozaki L.S., Alves J.M., Serrano M.G., et al. The genome of Cryptosporidium hominis. Nature 2004, 431:1107-1112.
217. Yang Y., Moir E., Kontopidis G., Taylor P., Wear M.A., Malone K., et al. Structure-based discovery of a family of synthetic cyclophilin inhibitors showing a cyclosporin-A phenotype in Caenorhabditis elegans. Biochem. Biophys. Res. Commun. 2007, 363:1013-1019.
218. Yokoyama K., Gillespie J.R., Van Voorhis W.C., Buckner F.S., Gelb M.H. Protein geranylgeranyltransferase-I of Trypanosoma cruzi. Mol. Biochem. Parasitol. 2008, 157:32-43.
219. Zaalouk T.K., Bajaj-Elliott M., George J.T., McDonald V. Differential regulation of beta-defensin gene expression during Cryptosporidium parvum infection. Infect. Immun. 2004, 72:2772-2779.
220. Zardi E.M., Picardi A., Afeltra A. Treatment of cryptosporidiosis in immunocompromised hosts. Chemotherapy 2005, 51:193-196.
221. Zhang L., Sheoran A.S., Widmer G. Cryptosporidium parvum DNA replication in cell-free culture. J. Parasitol. 2009, 95:1239-1242.
222. Zhou H.C., Gao Y.H., Zhong X., Wang H. Dynamin like protein 1 participated in the hemoglobin uptake pathway of Plasmodium falciparum. Chin. Med. J. (Engl). 2009, 122:1686-1691.